Who is sponsoring NCT04699214?

NCT04699214 is sponsored by Yong Chen.

What drugs are being tested in NCT04699214?

Interventions in NCT04699214: Endostar (recombinant human endostatin injection), Chemotherapy AI.

What condition does NCT04699214 study?

NCT04699214 studies Other Disorders of Soft Tissues.

Is NCT04699214 still recruiting?

NCT04699214 is currently status unknown. Last updated 7 January 2021.

Last reviewed 2021-01-07 · How we verify

NCT04699214

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment

Status unknown Phase 2 Last updated 7 January 2021

What this trial tests

Phase 2 trial testing Endostar (recombinant human endostatin injection) in Other Disorders of Soft Tissues in 210 participants. Status unknown.

Timeline

1 September 2020

Primary endpoint
31 August 2023

31 August 2023

Quick facts

Lead sponsor	Yong Chen
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	210
Start date	1 September 2020
Primary completion	31 August 2023
Estimated completion	31 August 2023
Sites	1 location across China

Drugs / interventions tested

Endostar (recombinant human endostatin injection) — full drug profile →
Chemotherapy AI — full drug profile →

Conditions studied

Other Disorders of Soft Tissues — all drugs for Other Disorders of Soft Tissues →

Sponsor

Yong Chen — full company profile →

Who can join

Adults 18 to 80, any sex, with Other Disorders of Soft Tissues. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the effectiveness, safety and tolerability of Endostar (recombinant human endostatin) combined with AI chemotherapy in adjuvant treatment after radical resection of recurrent soft tissue sarcoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The role of angiogenesis in melanoma: Clinical treatments and future expectations.
Wu Z, Bian Y, Chu T, Wang Y, et al · · 2022 · cited 25× · PMID 36588679 · DOI 10.3389/fphar.2022.1028647

Verify or expand the search:

Other Yong Chen trials

Trials by the same sponsor.

NCT05827770 — The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma · Phase 2 · unknown
NCT05106023 — To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma · Phase 2 · unknown
NCT04765228 — Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04699214 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yong Chen
Last refreshed: 7 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04699214.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing